Exposure to changes in the healthcare and long-term care systems, medical fees, drug prices and regulations
First written in FY2016. 23 of 27 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Important challenges include promoting DX through the use of AI and ICT and responding to work-style reform for healthcare professionals, with the aim of establishing an efficient, high-quality healthcare delivery system.」
The healthcare system, shortages of healthcare professionals, the promotion of DX, and responses to work-style reform remain important challenges in the business environment. - 2026-05-12RestatedEarnings
「The promotion of medical DX, operational efficiency improvements and the establishment of a sustainable healthcare delivery system are required.」
The need to promote medical DX, improve operational efficiency and establish a sustainable healthcare delivery system has been reaffirmed. - FY2026-H1RestatedAnnual report
「In the medical industry in which the group operates, various initiatives began in fiscal 2024, including the 8th Medical Care Plan, the 4th Medical Cost Optimization Plan, and work-style reform for physicians. In addition, revisions to the add-on for establishing a system to promote medical DX are driving digitalization in healthcare settings, and the establishment of an efficient, effective, high-quality healthcare delivery system continues to be required.」
The 8th Medical Care Plan, the 4th Medical Cost Optimization Plan, work-style reform for physicians, and revisions to the add-on for establishing a system to promote medical DX are presented as institutional and policy factors affecting the healthcare delivery system. - FY2025-H1RestatedAnnual report
「In the medical industry in which the group operates, various initiatives have started, including the 8th Medical Care Plan, the 4th Medical Cost Optimization Plan, and work-style reform for physicians. The establishment of an efficient, effective, high-quality healthcare delivery system continues to be required.」
Changes in the institutional and policy environment, including the Medical Care Plan, the Medical Cost Optimization Plan, and work-style reform for physicians, continue, and the establishment of a high-quality healthcare delivery system is required. - FY2024-Q3RestatedAnnual report
「Following the change in the legal classification of COVID-19 under the Infectious Diseases Control Law, revisions were made to subsidies for securing hospital beds for medical institutions and special provisions for medical reimbursement rates.」
Revisions to subsidies for securing hospital beds and special provisions for medical reimbursement rates following the change in the legal classification under the Infectious Diseases Control Law continue to be presented as system changes. - FY2024-Q2RestatedAnnual report
「In the medical industry in which the group operates, following the change in the legal classification of COVID-19 under the Infectious Diseases Control Law, revisions were made to subsidies for securing hospital beds for medical institutions and special provisions for medical reimbursement rates.」
Following the change in the legal classification under the Infectious Diseases Control Law, revisions to subsidies for securing hospital beds and special provisions for medical reimbursement rates were implemented, continuing to demonstrate the exposure to system changes in specific terms. - FY2024-Q1MaterialisedAnnual report
「Following the change in the legal classification of COVID-19 under the Infectious Diseases Control Law, revisions were made to subsidies for securing hospital beds for medical institutions and special provisions for medical reimbursement rates. The establishment of an efficient, effective, high-quality healthcare delivery system continues to be required.」
Following the change in the legal classification under the Infectious Diseases Control Law, revisions to subsidies for securing hospital beds and special provisions for medical reimbursement rates were implemented, demonstrating the exposure to system changes through specific changes. - FY2023-Q2RestatedAnnual report
「In the medical industry in which the group operates, the healthcare delivery system at times came under strain due to pressure on fever outpatient clinics and an increase in infections among healthcare professionals caused by the seventh wave of COVID-19, among other factors. The industry continues to require the establishment of an efficient, effective, high-quality healthcare delivery system capable of responding to COVID-19 and other infectious diseases.」
While the seventh wave caused pressure on fever outpatient clinics and an increase in infections among healthcare professionals, the establishment of a healthcare delivery system capable of responding to infectious diseases continues to be required. - FY2023-Q1RestatedAnnual report
「In the medical industry in which the group operates, the number of patients visiting medical institutions and the number of surgeries began to recover, among other factors. However, the industry continues to require the establishment of an efficient, effective, high-quality healthcare delivery system capable of responding to COVID-19 and other infectious diseases.」
While the number of patients visiting medical institutions and the number of surgeries are recovering, the establishment of a healthcare delivery system capable of responding to infectious diseases continues to be required. - FY2022RestatedAnnual report
「The group's business strategies, operating results, and other factors may be affected by changes in demographics and population structure, changes in disease patterns, innovation in medical technology, and trends in various government regulations.」
Changes in population and disease structure, medical technology, medical reimbursement rates, drug prices, and long-term care systems continue to be disclosed as institutional and structural risks affecting the business. - FY2021RestatedAnnual report
「Although the dispensing pharmacy business was affected by drug price revisions, its performance remained solid due to management efficiency improvements and a series of acquisitions of small-format stores, among other factors.」
While exposure to changes in the relevant systems, including drug price revisions, continues to affect results, the company explains that it responded through efficiency improvements and M&A. - FY2021-Q1RestatedAnnual report
「The dispensing pharmacy business remained in a difficult state due to the impact of revisions to dispensing fees and drug prices, as well as restrictions on visits to medical institutions caused by the spread of COVID-19.」
Exposure to changes in the relevant systems through revisions to dispensing fees and drug prices continued, and the quarter was also affected by restrictions on visits to medical institutions. - FY2020RestatedAnnual report
「In the medical industry in which the group operates, the April medical reimbursement rate revision prioritized reducing the burden on healthcare professionals and promoting work-style reform for physicians and others, while differentiation and strengthening of medical functions, cooperation, and the promotion of integrated community care systems were identified as basic perspectives. Medical institutions and companies across the industry are therefore required to establish broad-based cooperation and efficient operating structures over the medium to long term.」
Medical reimbursement rate revisions, integrated community care systems, and the differentiation and coordination of medical functions continue to be cited as institutional and structural factors affecting the business environment. - FY2020-Q3RestatedAnnual report
「In the medical industry in which the group operates, healthcare system reform is progressing against a backdrop of medical costs that continue to rise with advances in medicine and the declining birthrate and aging population. Medical institutions and companies across the industry are required to establish broad-based cooperation and efficient operating structures over the medium to long term to realize the Regional Healthcare Vision.」
Against a backdrop of rising medical costs, the declining birthrate and aging population, healthcare system reform, and the Regional Healthcare Vision, the need for cooperation and efficient operating structures continues. - FY2020-Q2RestatedAnnual report
「In the medical industry in which the group operates, healthcare system reform is progressing against a backdrop of medical costs that continue to rise with advances in medicine and the declining birthrate and aging population. Medical institutions and companies across the industry are required to establish broad-based cooperation and efficient operating structures over the medium to long term.」
The continuing rise in medical costs, the declining birthrate and aging population, and healthcare system reform mean that medical institutions and industry companies continue to be required to cooperate and establish efficient operating structures. - FY2020-Q1RestatedAnnual report
「In the medical industry in which the group operates, healthcare system reform is progressing against a backdrop of medical costs that continue to rise with advances in medicine and the declining birthrate and aging population. Medical institutions and companies across the industry are required to establish broad-based cooperation and efficient operating structures over the medium to long term.」
Changes in the institutional and business environment driven by rising medical costs, healthcare system reform, and the declining birthrate and aging population continue to be evident. - FY2019-Q3RestatedAnnual report
「In the medical industry in which the group operates, the medical reimbursement rate revision implemented in April last year was negative overall, and medical institutions and companies across the industry are required to establish broad-based cooperation and efficient operating structures over the medium to long term.」
Exposure to changes in the relevant systems, whereby a negative revision to medical reimbursement rates affects the business environment, and the continuing need for medical institutions and industry companies to cooperate and improve efficiency remain. - FY2019-Q2RestatedAnnual report
「In the medical industry in which the group operates, the dual revision of medical and long-term care reimbursement rates was implemented in April, with reimbursement prices for medical materials and drug prices reduced substantially in particular. In addition, the Regional Healthcare Vision, which sets out the future healthcare delivery system toward 2025, was formulated in all prefectures by March this year, and efforts are progressing to establish systems that provide medical care, long-term care, and welfare services seamlessly within each region, including the development of integrated community care systems.」
The company has reaffirmed that reductions in reimbursement prices and drug prices resulting from the dual revision of medical and long-term care reimbursement rates have already been implemented. It explains that the Regional Healthcare Vision has been formulated in all prefectures and that development of integrated community care systems is also progressing. - FY2019-Q1MaterialisedAnnual report
「The dual revision of medical and long-term care reimbursement rates was implemented in April, with reimbursement prices for medical materials and drug prices reduced substantially in particular.」
The previously disclosed changes to systems governing medical and long-term care reimbursement rates, drug prices, and other items were implemented in April 2018, and their impact has actually emerged in the results of the dispensing pharmacy and life care businesses. - FY2018RestatedAnnual report
「The April 2018 dual revision of medical and long-term care reimbursement rates was also implemented in line with this direction set by the government.」
Exposure to changes in the relevant systems, whereby revisions to medical and long-term care reimbursement rates may affect the business environment and results, remains. - FY2018-Q3RestatedAnnual report
「In the medical industry in which the group operates, continued investment and transformation from a medium- to long-term perspective are required to address next fiscal year's dual revision of medical and long-term care reimbursement rates, the redevelopment of social infrastructure amid the declining birthrate and aging population, particularly in urban areas, and the response to advanced medical care.」
The dual revision of medical and long-term care reimbursement rates, the redevelopment of social infrastructure amid the declining birthrate and aging population, and the response to advanced medical care continue to be identified as factors affecting the business environment. - FY2018-Q2RestatedAnnual report
「In the medical industry in which the group operates, investment and transformation from a medium- to long-term perspective are required as the dual revision of medical and long-term care reimbursement rates is scheduled for next year, medical costs continue to rise amid the declining birthrate and aging population, disease patterns change, and the industry responds to advanced medical care.」
Exposure to institutional and structural changes remains, including the dual revision of medical and long-term care reimbursement rates, rising medical costs, changes in disease patterns, and the response to advanced medical care, all of which affect the business environment. - FY2018-Q1RestatedAnnual report
「In the medical industry in which the group operates, investment and transformation from a medium- to long-term perspective are required as the dual revision of medical and long-term care reimbursement rates is scheduled for next year and as healthcare providers develop their future vision under the Regional Healthcare Vision.」
The existing exposure to changes in the relevant systems, whereby revisions to medical and long-term care reimbursement rates affect the business environment, remains evident with the next fiscal year's dual revision approaching. - FY2017-Q3RestatedAnnual report
「Although the group was affected by revisions to medical reimbursement rates, drug prices, and reimbursement prices, revenue and profit increased as project performance and the performance of long-term care facilities improved as planned, among other factors.」
Revisions to medical reimbursement rates, drug prices, and reimbursement prices continue to affect results. - FY2017-Q2RestatedAnnual report
「Although our Group was affected by revisions to medical service fees, drug prices and reimbursement prices, revenue and profit increased as project revenue was recognized ahead of the initial plan in some cases, among other factors.」
Revisions to medical reimbursement rates, drug prices, and reimbursement prices continue to affect results. - FY2017-Q1MaterialisedAnnual report
「Profit declined due to the recognition of advisory fees related to the business integration, the effects of revisions to reimbursement prices and dispensing fees, and the concentration of project revenue recognition in the second half of the year to a greater extent than usual.」
Revisions to reimbursement prices and dispensing fees occurred during the quarter as factors reducing profit, and the impact of exposure to changes in the relevant systems was reflected in results. - FY2016First statedAnnual report
「The group's business strategies, operating results, and other factors may be affected by changes in demographics and population structure, changes in disease patterns, innovation in medical technology, and trends in various government regulations.」
The company states that revisions to medical reimbursement rates and drug prices, reductions in long-term care reimbursement, and regulations such as the Pharmaceutical Affairs Law and Long-Term Care Insurance Act may affect its business.